2017
Serum Matrix Metalloproteinase-7, Respiratory Symptoms, and Mortality in Community-Dwelling Adults. MESA (Multi-Ethnic Study of Atherosclerosis)
Armstrong HF, Podolanczuk AJ, Barr RG, Oelsner EC, Kawut SM, Hoffman EA, Tracy R, Kaminski N, McClelland RL, Lederer DJ. Serum Matrix Metalloproteinase-7, Respiratory Symptoms, and Mortality in Community-Dwelling Adults. MESA (Multi-Ethnic Study of Atherosclerosis). American Journal Of Respiratory And Critical Care Medicine 2017, 196: 1311-1317. PMID: 28570100, PMCID: PMC5694831, DOI: 10.1164/rccm.201701-0254oc.Peer-Reviewed Original ResearchConceptsInterstitial lung abnormalitiesMatrix metalloproteinase-7Serum MMP-7Serum MMP-7 levelsMMP-7 levelsCommunity-dwelling adultsRespiratory symptomsOutcome dataOdds of ILAMetalloproteinase-7Serum matrix metalloproteinase-7Subclinical interstitial lung diseaseCause mortality ratesIdiopathic pulmonary fibrosisInterstitial lung diseaseLog unit incrementExertional dyspneaCause mortalityLung functionPulmonary fibrosisCox regressionLung diseasePotential confoundersPrognostic biomarkerLung abnormalities
2016
Validation of the prognostic value of MMP‐7 in idiopathic pulmonary fibrosis
Tzouvelekis A, Herazo‐Maya J, Slade M, Chu J, Deiuliis G, Ryu C, Li Q, Sakamoto K, Ibarra G, Pan H, Gulati M, Antin‐Ozerkis D, Herzog EL, Kaminski N. Validation of the prognostic value of MMP‐7 in idiopathic pulmonary fibrosis. Respirology 2016, 22: 486-493. PMID: 27761978, PMCID: PMC5352520, DOI: 10.1111/resp.12920.Peer-Reviewed Original ResearchConceptsTransplant-free survivalIdiopathic pulmonary fibrosisMMP-7 concentrationsMatrix metalloproteinase-7IPF patientsCause mortalityPulmonary fibrosisHealthy controlsMultivariate Cox proportional hazards modelCox proportional hazards modelPulmonary function parametersVariable clinical courseBaseline pulmonary function parametersProportional hazards modelIPF biomarkersProgressive diseaseClinical coursePoor prognosisPrognostic valueVital capacityIndependent biomarkerLung capacityPrognostic thresholdPlasma concentrationsMortality risk
2013
Association Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis
Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, Gibson KF, Seibold MA, Brown KK, Talbert JL, Markin C, Kossen K, Seiwert SD, Murphy E, Noth I, Schwarz MI, Kaminski N, Schwartz DA. Association Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis. JAMA 2013, 309: 2232-2239. PMID: 23695349, PMCID: PMC4545271, DOI: 10.1001/jama.2013.5827.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisChicago cohortPulmonary fibrosisImproved survivalPromoter polymorphismInterstitial lung disease clinicMUC5B Promoter PolymorphismPrimary end pointNumber of patientsTT genotype groupCommon risk polymorphismsChicago patientsIPF mortalityMedian followCause mortalityCumulative incidenceMechanisms of diseaseDisease clinicRetrospective studyVital capacityClinical trialsBlood concentrationsClinical covariatesMAIN OUTCOMETreatment status